Massimo Di Maïo

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 478 citations · Full text

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

Massimo Di Maïo, Ethan Basch, Fabrice Denis et al. · Annals of Oncology · 2022 · 435 citations · Full text

Surgical Oncology, Medicine, Cancer Management +10

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 386 citations

Advanced Ovarian Cancer, Medicine, Metronomic Therapy +7

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo et al. · Journal of Clinical Oncology · 2010 · 301 citations · Full text

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo et al. · Journal of Clinical Oncology · 2012 · 232 citations · Full text